Jul 02, 2024 Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Jul 02, 2024 Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
Jun 24, 2024 Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
May 13, 2024 Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 10, 2024 Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
Mar 22, 2024 Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Mar 18, 2024 Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
Jan 29, 2024 Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
Jan 11, 2024 Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
Dec 18, 2023 U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer